Scientific publications for BioPredictive non-invasive diagnostics
Peer-reviewed studies validating BioPredictive blood-test diagnostics for liver disease — from first-in-class development cohorts to long-term meta-analyses.
175/435
Matches for
“prognosis”
-
Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.
…test combination improves the liver-prognosis assessment in chronic hepatitis C (CHC…
-
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
…fibrosis with impaired liver-related prognosis. We aimed to compare blood fibrosis…
-
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
…These tools might help physicians determine prognosis at earlier stages and discuss…
-
Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
…Patients' prognosis decreased as liver stiffness and FibroTest increased. In multivariate analysis…
-
Systematic review: Investigating the prognostic performance of four non-invasive tests in alcohol-related liver disease.
…bias assessment using Quality in Prognosis Studies tool. ### Results Searches produced 25…
-
Prognostic value of the combined use of transient elastography and fibrotest in patients with chronic hepatitis B.
### Background & Aims Liver stiffness (LS) measurement using transient elastography and the FibroTest…
-
Non-invasive diagnosis and biomarkers in alcohol-related liver disease. Review
…diagnose more severe forms of ALD and to predict prognosis of patients.
-
Noninvasive Assessment of Liver Fibrosis.
### Background The prognosis and management of chronic liver diseases greatly depend on…
-
Liver fibrosis markers in alcoholic liver disease. Review
…Staging of liver fibrosis is essential to define prognosis and management of…
-
FibroTest (FT) has similar accuracy for cirrhosis in 'intention-to-diagnose' which is superior to transient elastography (TE) in chronic hepatitis B.
-
Commentary: prognostication of chronic hepatitis B - are Fibrotest and Fibroscan the final answers? Authors' reply.
-
Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis.
### Background & Aims In patients with compensated alcohol-related cirrhosis, reliable prognostic biomarkers…
-
Non-invasive diagnosis of steatosis, inflammatory changes and liver fibrosis in patients with non-alcoholic fatty liver diseases. Pilot study.
…Early detection of liver disease may improve the prognosis of these patients.
-
Role of Non-hepatic Medical Comorbidity and Functional Limitations in Predicting Mortality in Patients with HCV.
### Background Medical comorbidities and functional status limitations are determinants of mortality in…
-
Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. Review
Alcoholic liver disease (ALD) consists of a broad spectrum of disorders, ranging…
-
An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. Key publication
…viral load testing accurately defined the prognosis and the inactive carrier status.
-
Editorial: FibroTest to predict liver-related mortality in NAFLD. Should this change the diagnostic algorithm in NAFLD?
-
Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.
…damage and to establish a prognosis. Utility of non-invasive markers of…
-
Noninvasive Assessment of Liver Fibrosis. Key publication Review
-
Prevalence of liver fibrosis and cirrhosis in 699 Moroccan patients with chronic hepatitis C.
### Introduction chronic hepatitis C (CHC) can cause severe complications, including fibrosis and…
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
…a validated biomarker for the prognosis of patients with chronic liver disease.
-
Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers.
### Background In recent years noninvasive methods have been evaluated for the assessment…
-
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.
### Background FibroTest (FT) is the most frequently used serum fibrosis marker and…
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review
### Background Chronic HCV is one of the major causes of morbidity and…
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
[The prediction and validation of liver fibrosis by a noninvasive model and validation in patients with chronic hepatitis B].
### Objective To develop a simple model for the noninvasive diagnosis of liver…
-
Non-invasive diagnosis of hepatitis B virus-related cirrhosis. Review
…chosen and to predict the prognosis of patients with CHB. Liver biopsy…
-
The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
### Aim To assess the diagnostic value of FibroTest to discriminate between insignificant…
-
Concordance of non-invasive serology-based scoring indices and transient elastography for liver fibrosis and cirrhosis in chronic hepatitis C.
Aim To assess concordance of eight frequently used serology-based scoring indices…
-
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.
### Objectives Staging liver fibrosis in chronic viral hepatitis C (HCV) patients is…
-
[Prognosis assessment of alcoholic liver disease: how and why?]. Review
Alcoholic liver disease (ALD) causes more than 5000 deaths per year in…
-
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
### Unlabelled The staging of liver fibrosis is pivotal for defining the prognosis…
-
Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
…70-0.82); for cirrhosis prognosis, AUCs of FT and APRI were…
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis.
### Aim To investigate the diagnostic accuracy of acoustic radiation force impulse (ARFI…
-
Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications.
### Background & Aims Noninvasive tests (NITs) of liver fibrosis have been suggested to…
-
The Distribution of Liver Steatosis, Fibrosis, Steatohepatitis and Inflammation Activity in Alcoholics According to FibroMax Test.
### Background The diagnosis of alcoholic liver diseases is based on the history…
-
Non-invasive diagnosis and follow-up of chronic infection with Hepatitis C Virus.
Hepatitis C virus (HCV) infection is a major cause of chronic liver…
-
Non-invasive diagnosis and follow-up of portal hypertension.
Compensated advanced chronic liver disease (cACLD) describes the spectrum of advanced fibrosis…
-
Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.
…Fibrosis assessment is essential to establish prognosis and treatment indication. We compared…
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
Commentary: prognostication of chronic hepatitis B--are Fibrotest and Fibroscan the final answers?
-
Validation of the Performance of A1HPV6, a Triage Blood Test for the Early Diagnosis and Prognosis of SARS-CoV-2 Infection.
### Background And Aims Apolipoprotein A1 (A1) and haptoglobin (HP) serum levels are…
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
FibroTest has been validated as a biomarker of fibrosis in patients with…
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
### Background/Aims According to guidelines, the histological diagnosis of severe alcoholic steatohepatitis…
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
### Objective To determine practices among physicians in Canada for the assessment of…
-
The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).
The aim of this study was to evaluate the diagnostic usefulness of…
-
Personalized management of cirrhosis by non-invasive tests of liver fibrosis. Review
Owing to the high prevalence of various chronic liver diseases, cirrhosis is…
-
Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.
### Aim To assess the diagnostic value of Fibrotest in comparison with liver…
-
FIB-4: a simple, inexpensive and accurate marker of fibrosis in HCV-infected patients.
-
Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The "VARES" Italian multicenter study.
The diagnostic utilities of ultrasonography (US), fatty liver index (FLI) and an…
-
Glycogenic hepatopathy. Review
### Background Glycogenic hepatopathy (GH) is a disorder associated with uncontrolled diabetes mellitus…
-
Hepatitis B: are non-invasive markers of liver fibrosis reliable? Review
Liver biopsy, which was traditionally considered to be the gold standard for…
-
Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.
### Background And Aims The FibroTest (FT) demonstrated excellent diagnostic performance in the…
-
FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Meta Analysis
…most important factors in determining prognosis and the need for active treatment…
-
Non-invasive assessment of liver fibrosis: are we ready?
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Non-invasive evaluation of liver fibrosis by transient elastography and biochemical markers in elderly inpatients.
### Aim The objective of this study was to evaluate liver fibrosis using…
-
FibroStic: a large confirmatory study for non-invasive biomarkers accuracy, if correctly interpreted.
-
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
-
Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. Review
The correct identification of patients at increased risk of non-alcoholic steatohepatitis…
-
Noninvasive diagnosis in alcohol-related liver disease.
### Background Alcohol-related liver disease (ALD) represents a major cause of death…
-
Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.
Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and…
-
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
### Background & Aims The aim of this study was to determine the diagnostic…
-
Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease.
### Purpose Transient elastography (FibroScan, [TE]) and serum fibrosis markers such as the…
-
FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C.
-
Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.
### Aim To assess the performance of several non-invasive markers and of…
-
Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection. Review
Chronic hepatitis B virus (HBV) infection is a major cause of liver…
-
Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes.
### Background Patients with diabetes are at risk for nonalcoholic fatty liver disease…
-
Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
**Background/Objectives**: Prior research has identified a significant association between heart disease…
-
Real-world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosis.
### Background Direct antiviral agents (DAA) showed very good results in terms of…
-
Transient elastography alone and in combination with FibroTest® for the diagnosis of hepatic fibrosis in alcoholic liver disease.
### Background & Aims The reliability of transient elastography (TE) to assess liver fibrosis…
-
Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy.
### Background And Aim Thrombocytopenia is frequently observed in patients with chronic hepatitis…
-
Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.
### Purpose To compare the diagnostic performance of acoustic radiation force impulse (ARFI…
-
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. Key publication
### Background Although the FibroTest has been validated as a biomarker to determine…
-
A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.
### Objectives Precise evaluation of the level of liver fibrosis is recommended in…
-
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
### Background HIV-monoinfected individuals are at high risk of nonalcoholic fatty liver…
-
Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. Key publication
The aim was to assess the utility of FibroTest-ActiTest (FT-AT…
-
The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. Key publication
### Background/Aims The aim was to identify a panel of biomarkers (AshTest…
-
Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Key publication
### Background & Aims Alcohol is the leading cause of cirrhosis and liver-related…
-
Accuracy of prognostic serological biomarkers in predicting liver fibrosis severity in people with metabolic dysfunction-associated steatotic liver disease: a meta-analysis of over 40,000 participants.
### Introduction A prognostic model to predict liver severity in people with metabolic…
-
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
### Background In cardiometabolic disorders, non-alcoholic fatty liver disease is frequent and…
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
…to enable the prediction of prognosis and inform treatment decisions. However, as…
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
These are the first World Health Organization (WHO) guidelines for the prevention…
-
Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Review
Patients with HIV have a proclivity to develop liver fibrosis, especially when…
-
Management of the patient with SVR. Review
In the current era of therapy with direct-acting antiviral (DAAs) drugs…
-
EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease.
-
Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.
### Background Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for…
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication
### Background Blood tests of liver injury are less well validated in non…
-
Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy?
-
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. Review
The assessment of the fibrotic evolution of chronic hepatitis has always been…
-
Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.
### Background Determining the stage of fibrosis by liver biopsy is important in…
-
Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
### Objectives To evaluate the diagnostic performance of seven non-invasive tests (NITs…
-
Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
### Background The Fibrotest-Actitest is a six-parameter scoring system that allows…
-
American Association for the Study of the Liver
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
### Background Performance of non-invasive fibrosis biomarkers may be influenced by aetiology…
-
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group.
Histological activity reflects the global assessment of basic necroinflammatory lesions and is…
-
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.
### Unlabelled To optimize the management of patients with chronic hepatitis C virus…
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection.
-
Stage of liver fibrosis in patients with congenital bleeding disorders and infected with hepatitis C virus.
### Introduction Hepatitis C virus (HCV) is the major cause of chronic liver…
-
Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation.
### Background Noninvasive laboratory tests have been widely used in the diagnosis of…
-
Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.
### Background The aim of this study was to compare noninvasive biomarkers, FibroTest…
-
Effective use of FibroTest to generate decision trees in hepatitis C.
### Aim To assess the usefulness of FibroTest to forecast scores by constructing…
-
Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. Key publication
### Background Since 1920, a decrease in serum cholesterol has been identified as…
-
Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease.
Chronic Obstructive Pulmonary Disease (COPD) and Non-Alcoholic Fatty Liver Disease (NAFLD…
-
Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review. Review
Haemophilia is an entity, wherein the HCV infection rate is greater than…
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
### Background & Objectives One of the multiple factors contributing to virological response in…
-
Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C.
### Background Liver biopsy is an imperfect gold standard for assessing the disease…
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
### Background & Aim Fibrosis is an independent predictor of death in nonalcoholic steatohepatitis…
-
Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.
In chronic hepatitis C, biopsy is the gold standard for assessment of…
-
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.
### Background/Aims In chronic hepatitis C, biopsy is the gold standard for…
-
Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.
### Objective Fibroscan (FS) is a reliable noninvasive method for the diagnosis of…
-
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
### Background And Aims Transient elastography (FibroScan; Echosens, Paris, France) is a novel…
-
Usefulness of noninvasive tests in nodular regenerative hyperplasia of the liver.
### Background The only way to diagnose nodular regenerative hyperplasia (NRH) is liver…
-
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
### Background Assessment of fibrosis progression in chronic liver disease relies upon non…
-
Noninvasive Indirect Markers of Liver Fibrosis in Alcoholics.
The aim of this study was to evaluate the diagnostic values of…
-
Diagnostic accuracy of the Coopscore© to predict liver fibrosis in human immunodeficiency virus/hepatitis B virus co-infection.
Background Non-invasive methods for assessing liver fibrosis are increasingly used as…
-
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
### Background/Aims The hepatitis C virus (HCV) infection is important cause of…
-
Clinical and genetic definition of serum bilirubin levels for the diagnosis of Gilbert syndrome and hypobilirubinemia.
-
Prediction for steatosis in type-2 diabetes: clinico-biological markers versus 1H-MR spectroscopy.
### Objectives The SteatoTest, fatty liver index (FLI) and hepatic steatosis index (HSI…
-
Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients.
Non-invasive biomarkers have gained popularity for estimating fibrosis stage. In our…
-
Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease.
### Background And Aim Significant hepatic fibrosis is prognostic of liver morbidity and…
-
Altered serum N-glycomics in chronic hepatitis B patients.
### Background We previously reported on serum N-glycans as markers for the…
-
Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Key publication
### Background The efficiency of transient elastography for the assessment of liver fibrosis…
-
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B.
### Background Aims Liver biopsy is the gold standard for assessing hepatitis B…
-
Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography.
### Objective Patients with short bowel syndrome (SBS) receiving long-term parenteral nutrition…
-
Noninvasive methods, including transient elastography, for the detection of liver disease in adults with cystic fibrosis.
### Background Liver disease is the third leading cause of mortality in patients…
-
Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive.
### Unlabelled The sequential algorithm for fibrosis evaluation (SAFE) and the Bordeaux algorithm…
-
Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.
Fibromax is a diagnostic tool composed of the combination of 4 non…
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
### Background And Aim One of the unmet needs in subjects with metabolic…
-
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease?
### Background Few data are available on chronic hepatitis C (CHC) in elderly…
-
Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis.
Changes in the liver and bile ducts observed in patients diagnosed with…
-
Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
### Objectives Combining noninvasive tests increases diagnostic accuracy for staging liver fibrosis in…
-
Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease.
### Background And Aims The PGAA index was one of the first composite…
-
Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.
### Background Non invasive methods for fibrosis evaluation remain to be validated longitudinally…
-
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Key publication
### Background FibroTest, a noninvasive method of measuring biomarkers of liver fibrosis, is…
-
Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review.
### Background Many blood tests have been proposed as alternatives to liver biopsy…
-
Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
### Objective The 2019 _Standards of Medical Care in Diabetes_ suggested that patients…
-
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients.
### Background/Aims The aim of this study was to compare the performance…
-
Noninvasive procedures to evaluate liver involvement in HIV-1 vertically infected children.
### Objectives : Progressive liver injury is a concern in HIV-infected children exposed…
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
### Background & Aims Chronic hepatitis C is both a virologic and fibrotic disease…
-
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. Key publication
### Background One of the unmet needs in patients with metabolic risks is…
-
Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison.
### Background And Aims Real-time shear wave elastography (2D-SWE) is a…
-
Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C.
### Background Non-invasive tests have been constructed and evaluated mainly for binary…
-
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.
### Aim To compare histological endpoint assessment using noninvasive alternatives to biopsy during…
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
### Background & Aims Nonalcoholic steatohepatitis (NASH) is a prevalent liver disease associated with…
-
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
### Background & Aims EPIC-3 is a prospective, international study that has demonstrated…
-
Non-alcoholic fatty liver disease biomarkers estimate cardiovascular risk based on coronary artery calcium score in type 2 diabetes: a cross-sectional study with two independent cohorts. Key publication
### Background Studies have demonstrated that coronary artery calcification on one hand and…
-
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
### Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as…
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
As of 2016, there is no evidence-based pathway to stratify the…
-
FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Meta Analysis
### Background The accurate diagnosis of hepatitis C virus (HCV)-related fibrosis is…
-
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection.
### Objectives The noninvasive serum markers, FibroTest-ActiTest (FT-AT), are an alternative…
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
Liver fibrosis is a common pathway leading to cirrhosis, which is the…
-
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.
### Objective Screening for advanced fibrosis (AF) resulting from metabolic dysfunction-associated steatotic…
-
Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. Key publication
In patients with non-alcoholic fatty liver disease (NAFLD) with or without…
-
Assessment of liver fibrosis: noninvasive means.
Liver biopsy, owing to its limitations and risks, is an imperfect gold…
-
Methodological aspects of the interpretation of non-invasive biomarkers of liver fibrosis: a 2008 update. Key publication Review
This review summarizes the methodological aspects of the interpretation of non-invasive…
-
Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest).
### Background FibroTest and elastography have been validated as biomarkers of liver fibrosis…
-
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
### Background Preliminary data suggest that performance of non-invasive markers for liver…
-
Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference. Key publication
-
External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. Key publication
### Background & Aims The Liver Cancer Risk test algorithm (LCR1-LCR2) is a…
-
External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. Key publication
### Background And Aims The liver cancer risk test (LCR1-LCR2) is a…
-
An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.
**Background:** The current definition of metabolic dysfunction-associated steatotic liver disease (MASLD…
-
Noninvasive evaluation of NAFLD. Review
A common clinical concern in patients with NAFLD is whether they have…
-
Systematic review with meta-analysis: direct comparisons of biomarkers for the diagnosis of fibrosis in chronic hepatitis C and B. Meta Analysis
### Background Blood tests and transient elastography (TE), proposed as alternatives to biopsy…
-
Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study. Key publication
### Background Studies have demonstrated that both lower limb arterial calcification and metabolic…
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
Traditionally a disease of hepatologists, nonalcoholic fatty liver disease (NAFLD) has recently…
-
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Key publication
### Background Biopsy is the usual gold standard for liver steatosis assessment. The…
-
Prospective direct comparison of non-invasive liver tests in outpatients with type 2 diabetes using intention-to-diagnose analysis. Key publication
### Background No prospective diagnostic studies have directly compared widespread non-invasive liver…
-
[Biomarkers for liver fibrosis: advances, advantages and disadvantages]. Review
Liver cirrhosis in Mexico is one of the most important causes of…
-
Non-invasive markers for hepatic fibrosis. Review
With great advancements in the therapeutic modalities used for the treatment of…
-
Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Key publication
-
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Key publication
Chronic hepatitis C remains a significant medical and economic burden in Canada…
-
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.
-
Prise en charge des personnes infectées par les virus de l’hépatite B ou de l’hépatite C — Rapport de recommandations 2014 Key publication
Showing the full result list. The page is server-rendered and not paginated.